In the spotlight: A novel CD37 antibody-drug conjugate Journal Article

  

Authors:	Lia Palomba, M.; Younes, A.
Article Title:	In the spotlight: A novel CD37 antibody-drug conjugate
Abstract:	In this issue of Blood, Deckert et al make a strong argument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its activity against B-cell lymphoma in in vitro and in vivo preclinical studies. © 2013 by The American Society of Hematology.
Keywords:	cancer survival; treatment outcome; unclassified drug; review; nonhuman; rituximab; antineoplastic agent; antineoplastic activity; drug potency; drug effect; survival time; b cell lymphoma; cell cycle arrest; microtubule; metaphase; prometaphase; cd37 antigen; humoral immune deficiency; priority journal; imgn 529
Journal Title:	Blood
Volume:	122
Issue:	20
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2013-11-14
Start Page:	3397
End Page:	3398
Language:	English
DOI:	10.1182/blood-2013-09-526384
PROVIDER:	scopus
PUBMED:	24235129
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84888233707&partnerID=40&md5=4d87fa4c5a3be3ed39d2dd3730eac2fe
Notes:	Export Date: 2 January 2014 -- CODEN: BLOOA -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/48309